Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,996,650
  • Shares Outstanding, K 145,597
  • Annual Sales, $ 9,836 M
  • Annual Income, $ 1,161 M
  • 60-Month Beta -0.04
  • Price/Sales 3.35
  • Price/Cash Flow 12.22
  • Price/Book 2.16
Trade BIIB with:

Options Overview Details

View History
  • Implied Volatility 42.27% ( +3.97%)
  • Historical Volatility 23.73%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 42.27% on 07/23/24
  • IV Low 19.53% on 09/12/23
  • Put/Call Vol Ratio 0.65
  • Today's Volume 976
  • Volume Avg (30-Day) 1,268
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 30,144
  • Open Int (30-Day) 37,637

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 3.99
  • Number of Estimates 26
  • High Estimate 6.04
  • Low Estimate 3.43
  • Prior Year 4.02
  • Growth Rate Est. (year over year) -0.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
220.02 +1.94%
on 06/26/24
238.00 -5.76%
on 07/12/24
+0.29 (+0.13%)
since 06/21/24
3-Month
198.11 +13.21%
on 04/25/24
238.00 -5.76%
on 07/12/24
+31.11 (+16.10%)
since 04/23/24
52-Week
189.44 +18.40%
on 04/19/24
280.42 -20.01%
on 07/25/23
-52.45 (-18.95%)
since 07/21/23

Most Recent Stories

More News
Biogen Earnings Preview: What to Expect

Biogen is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

BIIB : 224.29 (-1.03%)
$SPX : 5,555.74 (-0.16%)
BBH : 176.61 (-0.83%)
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split

Revenue is climbing at these two drug companies -- and the trend should continue.

WMT : 70.65 (+0.38%)
CMG : 52.55 (-1.89%)
NVO : 133.28 (+0.08%)
NVDA : 122.59 (-0.77%)
REGN : 1,055.57 (-1.32%)
BIIB : 224.29 (-1.03%)
AMGN : 333.24 (-0.81%)
LLY : 878.29 (+1.42%)
VRTX : 490.32 (-1.13%)
Did Eli Lilly Just Get a Leg Up on Novo Nordisk?

Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk.

JPM : 210.33 (+0.02%)
NVO : 133.28 (+0.08%)
BIIB : 224.29 (-1.03%)
LLY : 878.29 (+1.42%)
3 Mega-Cap Stocks to Consider Before They're Worth $1 Trillion

Mega-cap stocks are the flavor of the season, and these three big names are the next set of contenders racing towards the $1 trillion market cap club.

NVDA : 122.59 (-0.77%)
MSFT : 444.85 (+0.43%)
META : 488.69 (+0.26%)
AMZN : 186.41 (+2.11%)
GOOGL : 181.79 (+0.07%)
AVGO : 163.77 (+1.68%)
AAPL : 225.01 (+0.47%)
TSLA : 246.38 (-2.04%)
GS : 492.15 (+1.05%)
LLY : 878.29 (+1.42%)
BIIB : 224.29 (-1.03%)
This Is Massive News for Eli Lilly Investors

A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate.

NVO : 133.28 (+0.08%)
BIIB : 224.29 (-1.03%)
LLY : 878.29 (+1.42%)
Is Biogen Stock Underperforming the Nasdaq?

Biogen underperforms the Nasdaq Composite, and analysts remain cautiously optimistic about the stock’s prospects.

BIIB : 224.29 (-1.03%)
$NASX : 17,997.35 (-0.06%)
VRTX : 490.32 (-1.13%)
Is Vertex Stock Outperforming the S&P 500?

Vertex has outperformed the S&P 500 over the past year, and analysts are moderately bullish on the stock.

VRTX : 490.32 (-1.13%)
$SPX : 5,555.74 (-0.16%)
BIIB : 224.29 (-1.03%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END

TLSA : 0.9001 (+0.01%)
LLY : 878.29 (+1.42%)
RHHBY : 38.2000 (-2.95%)
BIIB : 224.29 (-1.03%)
TGTX : 20.27 (-0.83%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

TLSA : 0.9001 (+0.01%)
LLY : 878.29 (+1.42%)
RHHBY : 38.2000 (-2.95%)
BIIB : 224.29 (-1.03%)
TGTX : 20.27 (-0.83%)
Is Amgen Stock Outperforming the S&P 500?

Amgen has outperformed the S&P 500, and analysts remain optimistic about the stock’s prospects because of the positive Phase 2 clinical trial data of its obesity drug MariTide.

AMGN : 333.24 (-0.81%)
$SPX : 5,555.74 (-0.16%)
LLY : 878.29 (+1.42%)
NVO : 133.28 (+0.08%)
BIIB : 224.29 (-1.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 231.57
2nd Resistance Point 229.81
1st Resistance Point 227.05
Last Price 224.29
1st Support Level 222.53
2nd Support Level 220.77
3rd Support Level 218.01

See More

52-Week High 280.42
Fibonacci 61.8% 245.66
Fibonacci 50% 234.93
Last Price 224.29
Fibonacci 38.2% 224.19
52-Week Low 189.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar